

Cell signaling proteomics in colorectal cancer

Madoz-Gúrpide J, Fernández-Carbonie F, Alfonso P, Casal I.

To gain further insight into alterations in cellular pathways, tumor profiling and marker discovery in colorectal cancer (CRC) we have used a new antibody microarray specific for cell signaling. Soluble protein extracts were prepared from paired tumor/normal biopsies of 11 patients diagnosed of colorectal carcinoma at different stages, four liver carcinomas were used as a reference. Antibody microarray analysis identified 46 proteins that were differentially expressed between normal colorectal epithelium and adenocarcinoma. These proteins gave a specific signature for CRC, different from other tumors, as well as a panel of novel markers and potential targets for CRC. Twenty-four proteins were validated by using a specific colorectal cancer tissue microarray and immunoblotting analysis. Together with some previously well known deregulated proteins in CRC (β -catenin, c-myc, or p63), we have found new potential markers preferentially expressed in CRC tumors: cytokeratin 13, calcineurin, Chk1, clathrin light chain, MAPK3, phospho-PTK2/FAK (S910) and MDM2. Chk1 antibodies were particularly effective in discriminating between tumoral and normal mucosa in CRC. Moreover, a global picture of alterations in signaling pathways in CRC was observed, including a significant up-regulation of different components of the EGFR and Wnt/ β -catenin pathways and the down-regulation of p14^{ARF}. The experimental approach described here should be applicable to other pathologies and neoplastic processes.

References

- Acton, S. L., Wong, D. H., Parham, P., Brodsky, F. M., and Jackson, A. P. (1993). *Mol Biol Cell* 4, 647-660
- Alfonso, P., Nunez, A., Madoz-Gurpide, J., Lombardia, L., Sanchez, L., and Casal, J. I. (2005). *Proteomics* 5, 2602-2611
- Birkenkamp-Demtroder, K., Christensen, L. L., Olesen, S. H., Frederiksen, C. M., Laiho, P., Aaltonen, L. A., Laurberg, S., Sorensen, F. B., Hagemann, R., and TF, O. R. (2002). *Cancer Res* 62, 4352-4363
- Cho, S. H., Toouli, C. D., Fujii, G. H., Crain, C., and Parry, D. (2005). *Cell Cycle* 4, 131-139
- Fearon, E. R., and Vogelstein, B. (1990). *Cell* 61, 759-767
- Frederiksen, C. M., Knudsen, S., Laurberg, S., and Orntoft, T. F. (2003). *J Cancer Res Clin Oncol* 129, 263-271
- Haab, B. B. (2005). *Mol Cell Proteomics* 4, 377-383
- Lakshmikuttyamma, A., Selvakumar, P., Kanthan, R., Kanthan, S. C., and Sharma, R. K. (2005). *J Cell Biochem* 95, 731-739
- Madoz-Gurpide, J., Lopez-Serra, P., Martinez-Torrecedrada, J. L., Sanchez, L., Lombardia, L., and Casal, J. I. (2006). *Mol Cell Proteomics* 5, 1471-1483
- Momand, J., Wu, H. H., and Dasgupta, G. (2000). *Gene* 242, 15-29
- Park, K. S., Kim, N. G., Kim, J. J., Kim, H., Ahn, Y. H., and Choi, K. Y. (1999). *Br J Cancer* 81, 1116-1121
- Vogelstein, B., and Kinzler, K. W. (2004). *Nat Med* 10, 789-799
- Weiner, T. M., Liu, E. T., Craven, R. J., and Cance, W. G. (1993). *Lancet* 342, 1024-1025
- Williams, N. S., Gaynor, R. B., Scoggin, S., Verma, U., Gokaslan, T., Simmang, C., Fleming, J., Tavana, D., Frenkel, E., and Becerra, C. (2003). *Clin Cancer Res* 9, 931-946